Coronary bifurcation lesions account for approximately 15% of all percutaneous coronary interventions (PCI) performed. Although clinical outcomes after PCI have been improved considerably, PCI of bifurcation lesions remains to be associated with adverse clinical events, when compared with non-bifurcation PCI. Therefore, several dedicated bifurcation devices have been developed to improve clinical outcomes. The Tryton Side Branch Stent(™) is such device and is used in combination with a regular tubular balloon expandable stent in the main branch. Multiple single and multicenter registries and a patient pooled analysis including 900 patients have shown promising results regarding clinical outcomes after bifurcation PCI with Tryton. The pivotal Tryton IDE randomized trial is currently underway comparing the Tryton stent with side branch balloon angioplasty as side branch treatment in bifurcation lesions challenging the current dogma of provisional single stent strategy as treatment for coronary bifurcation lesions.